Effects of single and long-term administration of wheat albumin on blood glucose control: Randomized controlled clinical trials

European Journal of Clinical Nutrition

Volumn 59, Issue 3, 2005, Pages 384-392

  Kodama, T ^a   Miyazaki, T ^b   Kitamura, I ^a   Suzuki, Y ^a   Namba, Y ^c   Sakurai, J ^d   Torikai, Y ^d   Inoue, S ^d  

^a NISSHIN SEIFUN GROUP INC   (Japan)

^b Nisshin Engineering Inc   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYORITSU WOMEN'S UNIVERSITY   (Japan)

Author keywords

amylase inhibitor; Diabetes mellitus; Hemoglobin A1c (HbA1c); Postprandial blood glucose; Wheat albumin

Indexed keywords

ALBUMIN; AMYLASE; GLUCOSE; HEMOGLOBIN A1C;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FLATULENCE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERPHAGIA; HYPOGLYCEMIA; HYPOPHAGIA; IN VITRO STUDY; JAPAN; LONG TERM CARE; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; OUTPATIENT DEPARTMENT; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH DISEASE; VOMITING; WHEAT;

ADMINISTRATION, ORAL; ADULT; ALBUMINS; ALPHA-AMYLASE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRITICUM;

TRITICUM AESTIVUM;

EID: 15544369372     PISSN: 09543007     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602085     Document Type: Article

References (34)

1. Amano M, Ogawa H, Kojima K, Kamidaira T, Suetsugu S, Yoshihama M, Satoh T, Samejima T & Matsumoto I (1998): Identification of the major allergens in wheat flour responsible for baker's asthma. Biochem. J. 330, 1229-1234.
2. Baba S (1994): Alpha-glucosidase inhibitor. In Novel Development in Pharmacological Therapy of Diabetes. Baba S pp 53-54. Japan Churchill Livingstone. (in Japanese).
3. 1c. J. Clin. Invest. 57, 1652-1659.
4. Carrascosa M, Pascual F & Aresti S (1997): Acarbose-induced acute severe hepatotixicity. Lancet 349, 698-699.
5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M & STOP-NIDDM Trial Research Group (2002): Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359, 2072-2077.
6. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M & STOP-NIDDM Trial Research Group (2003): Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. J. Am. Med. Assoc. 290 486-494.
7. Choudhury A, Maeda K, Murayama R & DiMagno EP (1996): Character of a wheat amylase inhibitor preparation and effects on fasting human pancreaticobilary secretions and hormones. Gastroenterology 111, 1313-1320.
8. DePonte R, Parlamenti R, Petrucci T, Silano V & Tomasi M (1976): Albumin α-amylase inhibitor families from wheat flour. Cereal Chem. 53, 805-820.
9. The Diabetes Control and Complications Trial Research Group (1993): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. 329, 977-986.
10. Diaz-Gutierrez FL, Ladero JM & Diaz-Rubio M (1998): Acarbose-induced acute hepatitis. Am. J. Gastroenterol. 93, 481.
11. Frier BM (2002): Hypoglycemic valleys: an under-recognised problem in type 2 diabetes? Int. J. Clin. Pract. Suppl. 129, 12-19.
12. Fujimoto Y, Ohhira M, Miyokawa N, Kitamori S & Kohgo T (1998): Acarbose-induced hepatic injury. Lancet 351, 340.
13. Goto Y, Baba S, Nakagawa S, Kuzuya T, Hirata Y, Akunuma Y, Sakamoto N, Shigeta Y & Mimura G (1992): The availability for non-insulin dependent diabetes mellitus of α-glucosidase inhibitor AO-128. Phase III comparison test between double blind groups. Igaku No Ayumi 160 943-971. (in Japanese).
14. Japanese Ministry of Health and Public Welfare (1999): National survey of diabetes mellitus. 1997 (in Japanese).
15. Japanese Ministry of Health, Labor, and Public Welfare (2003): Brief report of the national survey of diabetes mellitus. 2002 (in Japanese).
16. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P & Munera CL (1998): Advantage of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J. Clin. Endocrinol. Metab. 83, 1515-1522.
17. Josse RG, Chiasson JL, Ryan EA, Lau DCW, Ross SA, Yale JF, Leiter LA, Maheux P, Tessier D, Wolever TMS, Gerstein H, Rodger NW, Dornan JM, Murphy LJ, Rabasa-Lhoret R & Meneilly GS (2003): Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res. Clin. Pract. 59, 37-42.
18. Kashlan N & Richardson M (1981): The complete amino acid sequence of a major wheat protein inhibitor of α-amylase. Phytochemistry. 20, 1781-1784.
19. Kawakami S, Arima T, Harada K, Miyazono H, Oketani M, Miyazaki H & Arima T (2001): Hepatic necrosis with cholestasis induced by long-term voglibose administration. Intern. Med. 40, 484-488.
20. Kneen E & Sandstedt RM (1943): An amylase inhibitor from certain cereals. J. Am. Chem. Soc. 65, 1247.
21. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM & Diabetes Prevention Program Research Group (2002): Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl. J. Med. 346, 393-403.
22. 1c in diabetes mellitus. New Engl. J. Med. 295, 417-420.
23. Koike D, Yamadera K & DiMagno EP (1995): Effect of a wheat amylase inhibitor on canine carbohydrate digestion, gastrointestinal function, and pancreatic growth. Gastroenterology 108, 1221-1229.
24. Maeda K, Hase T & Matsubara H (1983): Complete amino acid sequence of an alpha-amylase inhibitor in wheat kernel. Biochim. Biophys. Acta 743, 52-57.
25. Oda Y, Matsunaga T, Fukuyama K, Miyazaki T & Morimoto T (1997): Tertiary and quaternary structures of 0.19 α-amylase inhibitor from wheat kernel determined by X-ray analysis at 2.06-A resolution. Biochemistry 36, 13503-13511.
26. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N & Shichiri M (1995): Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28, 103-117.
27. Ohno T (1995): Investigation of gastrointestinal adverse effects by alpha-glucosidase inhibitor, especially the development of ileus. J. New Remedies Clin. 44, 1114-1116. (in Japanese).
28. Rosenstock J (2000): Treatment strategies and new therapeutic advances for type 2 diabetes. Diabet. Educ. 26 (Suppl), 14-18.
29. Saloranta C, Guitard C, Pecher E, De Pablos-Velasco P, Lahti K, Brunel P & Groop L (2002): Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 25, 2141-2146.
30. Scherbaum WA & Zimmet P (1995): The prevention of the NIDDM epidemic. IDF Bull. 40, 6-16.
31. Sodini G, Silano V, de Agazio M, Pocchiari F, Tentori L & Vivaldi G (1970): Purification and properties of a Triticum aestivum specific albumin. Phytochemistry 9, 1167-1172.
32. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE & Matthews DR (2001): UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44, 156-163.
33. UK Prospective Diabetes Study (UKPDS) Group (1998): Intensive blood-glucose control with sulpfonylureas or insulin compaired with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853.
34. Yanai H (2004): Statcel - The Usefull Add-in Software Forms on Excel 2nd Edition, Tokyo, Japan. OMS (in Japanese).